Strategic Shifts and Tactics of 14 Listed Companies Entering the Chronic Disease Management Market

VCBeat has observed that, over the past two years, an increasing number of listed companies have launched internet-based chronic disease management businesses, spanning multiple industries including medical devices, pharmaceuticals, and information services:

• Medical Device Industry: Yuwell Medical, Lepu Medical, Sinocare, Qianshan Pharmaceutical Machinery.




• Pharmaceutical Industry: Hybio Pharmaceutical, SL Pharma, Tonghua Dongbao, Forui Shares, Chase Sun Pharmaceutical, Guizhou Bailing, Kunming Pharmaceutical Group.




• Information Services Industry: Neusoft Corporation, Wonders Information, Winssun Medical.

The reasons for this transformation are multifaceted. For instance, while the growth rate of China’s pharmaceutical and medical device markets has slowed, the number of patients with chronic diseases has continued to rise rapidly, giving rise to a vast market for chronic disease management. Meanwhile, the maturity and widespread adoption of technologies such as mobile internet, the Internet of Things (IoT), and cloud computing have created technological opportunities for more efficient and high-quality chronic disease management.

VCBeat selects 14 listed companies from the medical devices, pharmaceuticals, and information services sectors to provide you with an in-depth analysis: Why are they transitioning into chronic disease management? What are their transformation pathways? And how are they implementing their respective chronic disease management businesses?

Industry professionals are welcome to add the author on WeChat at yeyurenlei to jointly discuss development trends in the healthcare industry.